Cargando…
Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
Doxorubicin (DOX) is an anthracycline antibiotic frequently used against a wide range of cancers, including breast cancer. Although the drug is effective as a treatment against cancer, many patients develop heart failure (HF) months to years following their last treatment with DOX. The challenge in...
Autores principales: | Abrahams, Carmelita, Woudberg, Nicholas J., Lecour, Sandrine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434835/ https://www.ncbi.nlm.nih.gov/pubmed/36050733 http://dx.doi.org/10.1186/s12944-022-01694-y |
Ejemplares similares
-
Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution
por: Woudberg, Nicholas J., et al.
Publicado: (2016) -
Coronary microcirculation damage in anthracycline cardiotoxicity
por: Galán-Arriola, Carlos, et al.
Publicado: (2021) -
Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020) -
High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway
por: Frias, Miguel A., et al.
Publicado: (2012)